Patient charities ink deals to wrap up the Justice Department's co-pay kickback probe

Close-up of two people shaking hands with other people in the background
Two patient co-pay charities are settling with the feds to escape patient kickback allegations. (Pixabay)

An industrywide federal probe into drugmakers' use of charitable foundations to allegedly offer kickbacks for prescriptions of its drugs has netted some big fish in the last two years. Now, for the first time, two of the charities involved in the case have agreed to settle. 

Good Days and Patient Access Network Foundation will shell out a combined $6 million to close U.S. Department of Justice claims they operated as pharma front funds to effectively pay patients to take their drugs. 

Good Days President Clorinda Walley said in a statement the foundation would "continue to comply with all regulatory requirements surrounding charitable copay assistance programs and we welcome further clarity and (Office of the Inspector General) guidance to ensure we can continue to put patients in need first."

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

As part of the deal, Good Days agreed to pay $2 million while PAN Foundation will shell out $4 million. Neither foundation admitted wrongdoing. 

RELATED: Mallinckrodt hit with new kickback charges same day as $15.4M settlement with feds

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.